search button

GLP‑1 receptor agonist on cardiovascular complications of diabetes mellitus

  • Authors:
    • Fengjun Liu
    • Yanhua Kong

  • View Affiliations

  • Published online on: January 20, 2020     https://doi.org/10.3892/etm.2020.8439
  • Pages: 2259-2265

  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Effects of glucagon‑like peptide‑1 (GLP‑1) receptor agonist on cardiovascular complications of diabetes mellitus (DM) were investigated. In total, 132 DM patients treated in Tengzhou Central People's Hospital from April 2013 to September 2016 were included. Of these, 71 cases treated with basic drugs plus GLP‑1 were the research group, and 61 cases treated with glipizide controlled release tablets the control group. The improvement of clinical efficacy of patients in the two groups after treatment was observed. The concentrations of FPG, HbAlc, TC, LDL‑C, and HDL‑C in serum of patients in the two groups before and after treatment were compared, and the incidence rate of cardiovascular disease complications of diabetes was recorded. Expression of FPG, HbAlc, TC, LDL‑C, and HDL‑C of patients in the two groups were further detected. ROC curve was drawn to analyze its predictive value. In terms of markedly effective treatment rate and overall effective rate, the research group was significantly better than the control group (P<0.05). After treatment, the concentrations of FPG, HbAlc, TC, LDL‑C, and HDL‑C in serum of patients in the research group were significantly lower than those in the control group (P<0.05). The incidence rate of cardiovascular diseases and residual vascular risks in the research group were significantly higher than those in the control group (P<0.05). After treatment, the AUC of FPG, HbAlc, TC, LDL‑C, and HDL‑C in serum for predicting cardiovascular complications in DM patients were, respectively, 0.742, 0.780, 0.737, 0.726, and 0.721. In conclusion, GLP‑1 receptor agonist can improve the clinical efficacy of patients. Through ROC curve, FPG, HbAlc, TC, LDL‑C and HDL‑C can be used as predictors of cardiovascular complications in DM patients, which has high clinical value.
View Figures
View References

Related Articles

Journal Cover

March-2020
Volume 19 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Liu F and Kong Y: GLP‑1 receptor agonist on cardiovascular complications of diabetes mellitus. Exp Ther Med 19: 2259-2265, 2020.
APA
Liu, F., & Kong, Y. (2020). GLP‑1 receptor agonist on cardiovascular complications of diabetes mellitus. Experimental and Therapeutic Medicine, 19, 2259-2265. https://doi.org/10.3892/etm.2020.8439
MLA
Liu, F., Kong, Y."GLP‑1 receptor agonist on cardiovascular complications of diabetes mellitus". Experimental and Therapeutic Medicine 19.3 (2020): 2259-2265.
Chicago
Liu, F., Kong, Y."GLP‑1 receptor agonist on cardiovascular complications of diabetes mellitus". Experimental and Therapeutic Medicine 19, no. 3 (2020): 2259-2265. https://doi.org/10.3892/etm.2020.8439